HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China

Table 3 Prevalence of drug-resistance mutations among ART-naïve participants (n = 118) and participants experiencing treatment failure (n = 214) in Hebei between 2012 and 2013

			3TC	ABC	AZT	D4T	DDI	FTC	TDF
Nucleoside reverse transcriptase inhibitors
M184V	1.69	27.57	H	L	S	S	P	H	S
Q151M	0.00	0.47	L	H	H	H	H	L	L
F116Y	0.00	0.47	S	P	P	P	P	S	S
M184I	0.00	1.87	H	P	S	S	S	H	S
T69N	0.85	2.34	S	S	S	S	P	S	S
T69i	0.00	0.47	M	M	M	M	M	M	M
A62V	0.00	1.87	S	S	S	S	S	S	S
M41L	0.00	5.14	S	P	L	L	P	S	P
D67S	0.00	0.47	S	S	P	P	S	S	S
V75I	0.85	0.47	S	S	S	P	P	S	S
V75L	0.00	2.80	S	S	S	P	P	S	S
T215I	0.00	0.93	S	P	L	L	P	S	S
T215Y	0.85	5.14	S	L	M	M	L	S	L
K70T	0.00	0.47	P	P	S	P	P	P	P
K70E	0.00	0.47	P	L	S	S	L	P	L
K70R	0.00	8.41	S	P	M	L	P	S	P
V75M	0.00	0.93	S	S	P	M	L	S	S
L210W	0.00	0.93	S	P	L	L	P	S	P
D67N	0.85	5.61	S	S	L	L	S	S	S
D67G	0.00	0.47	S	S	P	P	S	S	S
T215F	0.00	2.34	S	L	M	M	L	S	L
T215N	0.00	0.47	S	P	L	L	P	S	S
K219E	0.00	3.27	S	S	P	P	S	S	S
K219Q	0.00	2.34	S	S	P	P	S	S	S
L74I	0.00	1.40	S	L	S	S	H	S	S
L74V	0.00	0.93	S	M	S	S	H	S	S
K65R	0.00	1.87	M	M	S	M	H	M	H

			EFV	ETR	NVP	RPV
Non-nucleoside reverse transcriptase inhibitors
A98G	0.00	1.40	P	P	M	L
H221Y	0.00	6.54	P	P	P	P
K101E	0.00	3.27	L	L	M	M
K103N	1.69	15.89	H	S	H	S
K103S	0.00	0.47	M	S	H	S
K103T	0.00	0.47	L	S	H	S
V106A	0.00	0.93	M	P	H	S
V106M	0.00	1.40	H	S	H	S
V106I	7.63	8.88	S	S	S	S
V108I	0.00	3.74	P	S	L	S
E138Q	0.00	2.34	P	P	P	L
E138G	0.85	0.0	P	P	P	L
V179E	4.24	2.80	P	P	P	P
V179D	0.85	0.47	P	P	P	P
Y181C	0.00	11.68	M	M	H	M
Y188L	0.00	1.40	H	L	H	H
Y188C	0.00	0.47	M	S	H	S
Y188W	0.00	0.47	S	S	S	S
G190S	0.00	3.74	H	L	H	L
G190A	0.00	5.14	M	L	H	L
G190R	0.00	0.47	S	S	S	S
P225H	0.00	1.87	M	S	L	S
F227L	0.00	0.93	L	S	M	S
M230L	0.85	0.47	M	M	H	M
M230I	0.00	0.93	L	L	M	M
K238T	0.00	2.34	L	S	M	S
V90I	0.00	5.14	S	S	S	S
E138A	0.00	0.93	S	P	S	L
E138K	0.00	0.47	P	P	P	M

Some (italics) of drugs listed in the Stanford HIV DR database are used in China
S susceptible, P potential low-level resistance, L low-level resistance, M intermediate resistance, H high-level resistance, ATV/r atazanavir/r, NFV/r nelfinavir plus ritonavir, LPV/r lopinavir plus ritonavir, 3TC lamivudine, ABC abacavir, AZT zidovudine, D4T stavudine, DDI didanosine, FTC emtricitabine, TDF tenofovir, EFV efavirenz, ETR etravirine, NVP nevirapine

ISSN: 1742-6405